Nuvalent Inc (NUVL)vsRegeneron Pharmaceuticals Inc (REGN)
NUVL
Nuvalent Inc
$123.96
0.00%
HEALTHCARE · Cap: $9.81B
REGN
Regeneron Pharmaceuticals Inc
$784.36
+1.59%
HEALTHCARE · Cap: $78.31B
Smart Verdict
WallStSmart Research — data-driven comparison
REGN leads profitability with a 27.9% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 66/100 (B-).
NUVL
Avoid25
out of 100
Grade: F
REGN
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NUVL.
Margin of Safety
+45.7%
Fair Value
$1415.47
Current Price
$784.36
$631.11 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Strong operational efficiency at 33.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
Trading at 8.3x book value
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : NUVL
The strongest argument for NUVL centers on Altman Z-Score.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : NUVL
The primary concerns for NUVL are Price/Book, Revenue Growth, EPS Growth.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
NUVL profiles as a value stock while REGN is a growth play — different risk/reward profiles.
NUVL carries more volatility with a beta of 1.14 — expect wider price swings.
REGN is growing revenue faster at 16.7% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (66/100 vs 25/100), backed by strong 27.9% margins and 16.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Nuvalent Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nuvalent Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology, dedicated to the development of targeted therapies for cancer patients with genetically defined diseases. Leveraging its proprietary drug discovery platform, Nuvalent aims to innovate therapeutics that specifically address genetic mutations linked to tumor proliferation, thus enhancing treatment efficacy while minimizing adverse effects. With a promising pipeline of selective therapies, the company is well-positioned to capitalize on the expanding precision oncology market, demonstrating its commitment to revolutionizing cancer treatment and improving patient outcomes.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?